Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Pizzuti

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Cancers|April 5, 2020
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS TrialLaura Pizzuti, Eriseld Krasniqi, Chiara Mandoj, et al.
Journal of Cancer Research and Clinical Oncology|April 23, 2013
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancerClara Natoli, Patrizia Vici, Isabella Sperduti, et al.
BMC Cancer|February 8, 2017
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancerMaddalena Barba, Patrizia Vici, Laura Pizzuti, et al.
Cancer Biology & Therapy|April 8, 2017
Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapyCristiana Ercolani, Anna Di Benedetto, Irene Terrenato, et al.
Journal of Cellular Physiology|December 17, 2014
Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancerPatrizia Vici, Anna Crispo, Antonio Giordano, et al.
Oncotarget|October 9, 2014
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapyPatrizia Vici, Marcella Mottolese, Laura Pizzuti, et al.
Cancer Treatment Reviews|January 3, 2015
Triple positive breast cancer: a distinct subtype?Patrizia Vici, Laura Pizzuti, Clara Natoli, et al.
Cancer Science|May 8, 2024
HER2 mutation as an emerging target in advanced breast cancerGiulia Bon, Francesca Sofia Di Lisa, Lorena Filomeno, et al.
Neoplasia (New York, N.Y.)|September 28, 2023
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP studyGiulia Bon, Eriseld Krasniqi, Manuela Porru, et al.
Cancers|January 22, 2021
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future PerspectivesMichela Roberto, Antonio Astone, Andrea Botticelli, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Cancers|April 5, 2020
Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS TrialLaura Pizzuti, Eriseld Krasniqi, Chiara Mandoj, et al.
Journal of Cancer Research and Clinical Oncology|April 23, 2013
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancerClara Natoli, Patrizia Vici, Isabella Sperduti, et al.
BMC Cancer|February 8, 2017
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancerMaddalena Barba, Patrizia Vici, Laura Pizzuti, et al.
Cancer Biology & Therapy|April 8, 2017
Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapyCristiana Ercolani, Anna Di Benedetto, Irene Terrenato, et al.
Journal of Cellular Physiology|December 17, 2014
Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancerPatrizia Vici, Anna Crispo, Antonio Giordano, et al.
Oncotarget|October 9, 2014
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapyPatrizia Vici, Marcella Mottolese, Laura Pizzuti, et al.
Cancer Treatment Reviews|January 3, 2015
Triple positive breast cancer: a distinct subtype?Patrizia Vici, Laura Pizzuti, Clara Natoli, et al.
Cancer Science|May 8, 2024
HER2 mutation as an emerging target in advanced breast cancerGiulia Bon, Francesca Sofia Di Lisa, Lorena Filomeno, et al.
Neoplasia (New York, N.Y.)|September 28, 2023
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP studyGiulia Bon, Eriseld Krasniqi, Manuela Porru, et al.
Cancers|January 22, 2021
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future PerspectivesMichela Roberto, Antonio Astone, Andrea Botticelli, et al.
Pageof 12